CTRI/2020/07/026852招募中未知
Impact of Early versus late initiation of oral feeding after major benign gynecologic procedures and Cesarean Deliveries on rate of postoperative complications - A Randomised Control trial
All India Institute of Medical Sciences Jodhpur0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Primigravida and Previous one or two cesarean section , between age group of 18-40 years, with singleton pregnancy undergoing Uncomplicated Cesarean section -under regional anesthesia will be recruited postoperatively after signing written informed consent.
- •All subjects, between age 18-70yrs undergoing uncomplicated major benign gynecologic procedure will be recruited postoperatively after signing written informed consent.
排除标准
- •1.Age >70yrs, <18yrs , multiple pregnancy , Medical disorders as (hypertension, diabetes, liver or kidney diseases)
- •2.Complications during surgery as excessive bleeding, intestinal injury, or urinary bladder injury.
- •3.Cancer surgery.
研究者
相似试验
进行中（未招募）
1 期
An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of TMC207 os and pyrazinamide (JZ), m.d. of TMC207 os and rifampin (JR) or m. oral d. of TMC207 os and isoniazid and pyrazinamide (JHZ), compared to the 3 principle drugs of standard anti-tuberculosis treatment (HRZ) in treatment-naïve subjects with sputum-smear positive pulmonary tuberculosis. - N/ATuberculosisEUCTR2004-005142-12-GBTibotec Pharmaceuticals Limited60
进行中（未招募）
1 期
A Phase 1/2 open label study in MPS IIIB subjects to investigate the long term safety and effect of SBC-103 given by IV infusion.Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo BMedDRA version: 19.0 Level: LLT Classification code 10056918 Term: Sanfilippo's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 19.0 Level: PT Classification code 10056890 Term: Mucopolysaccharidosis III System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001983-20-GBAlexion Pharmaceuticals, Inc3
已完成
不适用
An Open-Label Phase I Study to Assess the Effect of Rifampicin in the Pharmacokinetics of Eribulin Mesylate (E7389) in Subjects with Advanced Solid Tumoursdrug metabolism / cancer10027656NL-OMON32968Eisai14
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Synovial SarcomaEUCTR2018-004243-23-ESilly S.A.23
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Synovial SarcomaEUCTR2018-004243-23-NLEli Lilly and Company34